<DOC>
	<DOCNO>NCT00827554</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) major tumor type worldwide , especially China sequence hepatitis B liver cirrhosis . Activation coagulation system occur commonly patient malignancy . Several study suggest anticoagulant therapy may improve survival patient malignancy . The low molecular weight heparin ( LMWHs ) lend study effect experimental model malignancy relative ease administration compare unfractionated heparin . The purpose present RCT determine whether addition LMWH transarterial chemoembolization ( TACE ) would improve HCC patient outcome compare TACE alone .</brief_summary>
	<brief_title>The Role Low Molecular Weight Heparins Hepatocellular Carcinoma</brief_title>
	<detailed_description>100 patient randomly assign receive either TACE alone TACE plus LMWH . A block every 4 participant stratify randomization accord portal vein cancer embolus use restrict randomization . LMWH consist nadroparin Ca give dose 4100 U twice daily 6 week TACE . The time progression ( TTP ) overall survival within two year use evaluate effect LMWH HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Adults patient diagnosis HCC amenable surgical resection , liver transplantation local ablative therapy 2 . Without metastasis liver 3 . Patients must least one tumor lesion meet follow criterion : 1 . The lesion accurately measure least one dimension accord RECIST criterion 2 . The lesion previously treat surgery , radiation therapy , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . 4 . ECOG performance status ( PS ) &lt; 2 5 . No prior target antiangiogenic therapy . Metronomic chemotherapy allow . At least 4 week since prior systemic chemotherapy 6 . ChildPugh class A B 7 . No significant renal impairment ( creatinine clearance &lt; 30 mL/minute ) patient dialysis 8 . Ability understand protocol agree sign write informed consent document 1 . HBSAg ( ) ï¼ŒAFP ( ) . 2. prothrombin time prolong 4 . 3. blood platelet count less 50000/L . 4 . Renal failure require dialysis . 5 . ChildPugh class C hepatic impairment . 6. clinically significant gastrointestinal bleeding within 30 day prior study entry . 7 . History organ allograft . 8 . Substance abuse ( current ) , psychological , social condition may interfere patient 's participation study evaluation study result . 9 . Known suspected allergy investigational agent agent give association trial . 10 . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Nadroparin</keyword>
	<keyword>low-molecular-weight heparin</keyword>
	<keyword>chemoembolization</keyword>
</DOC>